Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

ClinicalTrials.gov ID: NCT00456261

Public ClinicalTrials.gov record NCT00456261. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 10:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer

Study identification

NCT ID
NCT00456261
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
SCRI Development Innovations, LLC
Other
Enrollment
110 participants

Conditions and interventions

Conditions

Interventions

  • Bevacizumab Drug
  • Carboplatin Drug
  • Gemcitabine Drug
  • Pemetrexed Drug

Drug

Eligibility (public fields only)

Age range
70 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2007
Primary completion
Jan 31, 2010
Completion
Aug 31, 2012
Last update posted
May 2, 2022

2007 – 2012

United States locations

U.S. sites
18
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
Northeast Alabama Regional Medical Center Anniston Alabama 36207
NEA Baptist Clinic Jonesboro Arkansas 72401
Florida Cancer Specialists Fort Myers Florida 33901
Watson Clinic Center for Cancer Care and Research Lakeland Florida 33805
Northeast Georgia Medical Center Gainesville Georgia 30501
Wellstar Cancer Research Marietta Georgia 30060
Providence Medical Group Terre Haute Indiana 47802
Graves-Gilbert Clinic Bowling Green Kentucky 42101
Consultants in Blood Disorders and Cancer Louisville Kentucky 40207
Mercy Hospital Portland Maine 04101
Grand Rapids Clinical Oncology Program Grand Rapids Michigan 49503
Methodist Cancer Center Omaha Nebraska 68114
Cancer Care of Western North Carolina Asheville North Carolina 28801
Oncology Hematology Care Cincinnati Ohio 45242
Spartanburg Regional Medical Center Spartanburg South Carolina 29303
Associates in Hematology Oncology Chattanooga Tennessee 37404
Chattanooga Oncology Hematology Associates Chattanooga Tennessee 37404
Tennessee Oncology, PLLC Nashville Tennessee 37023

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00456261, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 2, 2022 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00456261 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →